Takara Bio, MolMed Conclude R&D Agreement for HIV Treatment

Takara Bio has signed a research and development agreement with MolMed S.p.A., an Italian company specialized in gene therapy treatments. Under the terms of the agreement, the two companies will develop a gene therapy treatment for AIDS. The partners plan to develop an HIV-1 derived lentivirus vector and subsequently establish a method to introduce the vector with therapeutic genes into hematopoietic stem cells of AIDS patients.

Japan Corporate News Network (http://www.japancorp.net/Article.Asp?Art_ID=9778)